Compile Data Set for Download or QSAR
Report error Found 308 Enz. Inhib. hit(s) with all data for entry = 10728
TargetSodium-dependent noradrenaline transporter(Human)
Esteve Pharmaceuticals

US Patent
LigandPNGBDBM562327(US11401270, Example 152 | (S)-4-(2-fluoro-4-(1-(2-...)
Affinity DataKi: <100nMAssay Description:Human norepinephrine transporter (NET) enriched membranes (5 μg) were incubated with 5 nM of radiolabeled [3H]-Nisoxetin in assay buffer contain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetVoltage-dependent calcium channel subunit alpha-2/delta-1(Human)
Esteve Pharmaceuticals

US Patent
LigandPNGBDBM562327(US11401270, Example 152 | (S)-4-(2-fluoro-4-(1-(2-...)
Affinity DataKi: <100nMAssay Description:Human α2δ-1 enriched membranes (2.5 μg) were incubated with 15 nM of radiolabeled [3H]-Gabapentin in assay buffer containing Hepes-KOH...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetSodium-dependent noradrenaline transporter(Human)
Esteve Pharmaceuticals

US Patent
LigandPNGBDBM562326(US11401270, Example 151 | (S)-4-(4-(1-(3- fluoroph...)
Affinity DataKi: <100nMAssay Description:Human norepinephrine transporter (NET) enriched membranes (5 μg) were incubated with 5 nM of radiolabeled [3H]-Nisoxetin in assay buffer contain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetSodium-dependent noradrenaline transporter(Human)
Esteve Pharmaceuticals

US Patent
LigandPNGBDBM562328(US11401270, Example 153 | (S)-8-amino-4-(2-fluoro-...)
Affinity DataKi: <100nMAssay Description:Human norepinephrine transporter (NET) enriched membranes (5 μg) were incubated with 5 nM of radiolabeled [3H]-Nisoxetin in assay buffer contain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetVoltage-dependent calcium channel subunit alpha-2/delta-1(Human)
Esteve Pharmaceuticals

US Patent
LigandPNGBDBM562328(US11401270, Example 153 | (S)-8-amino-4-(2-fluoro-...)
Affinity DataKi: <100nMAssay Description:Human α2δ-1 enriched membranes (2.5 μg) were incubated with 15 nM of radiolabeled [3H]-Gabapentin in assay buffer containing Hepes-KOH...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetSodium-dependent noradrenaline transporter(Human)
Esteve Pharmaceuticals

US Patent
LigandPNGBDBM562317(US11401270, Example 142 | (S)-4-(2-fluoro-4-(3- (m...)
Affinity DataKi: <100nMAssay Description:Human norepinephrine transporter (NET) enriched membranes (5 μg) were incubated with 5 nM of radiolabeled [3H]-Nisoxetin in assay buffer contain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetSodium-dependent noradrenaline transporter(Human)
Esteve Pharmaceuticals

US Patent
LigandPNGBDBM562316(US11401270, Example 141 | (S)-(2-chloro-4-(3- (met...)
Affinity DataKi: <100nMAssay Description:Human norepinephrine transporter (NET) enriched membranes (5 μg) were incubated with 5 nM of radiolabeled [3H]-Nisoxetin in assay buffer contain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetVoltage-dependent calcium channel subunit alpha-2/delta-1(Human)
Esteve Pharmaceuticals

US Patent
LigandPNGBDBM562316(US11401270, Example 141 | (S)-(2-chloro-4-(3- (met...)
Affinity DataKi: <100nMAssay Description:Human α2δ-1 enriched membranes (2.5 μg) were incubated with 15 nM of radiolabeled [3H]-Gabapentin in assay buffer containing Hepes-KOH...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetSodium-dependent noradrenaline transporter(Human)
Esteve Pharmaceuticals

US Patent
LigandPNGBDBM562319(US11401270, Example 144 | (S)-5-(2-fluoro-4-(3- (m...)
Affinity DataKi: <100nMAssay Description:Human norepinephrine transporter (NET) enriched membranes (5 μg) were incubated with 5 nM of radiolabeled [3H]-Nisoxetin in assay buffer contain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetSodium-dependent noradrenaline transporter(Human)
Esteve Pharmaceuticals

US Patent
LigandPNGBDBM562318(US11401270, Example 143 | (S)-7-fluoro-4-(2-fluoro...)
Affinity DataKi: <100nMAssay Description:Human norepinephrine transporter (NET) enriched membranes (5 μg) were incubated with 5 nM of radiolabeled [3H]-Nisoxetin in assay buffer contain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetSodium-dependent noradrenaline transporter(Human)
Esteve Pharmaceuticals

US Patent
LigandPNGBDBM562323(US11401270, Example 148 | (S)-8-(ethylamino)-4-(2-...)
Affinity DataKi: <100nMAssay Description:Human norepinephrine transporter (NET) enriched membranes (5 μg) were incubated with 5 nM of radiolabeled [3H]-Nisoxetin in assay buffer contain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetSodium-dependent noradrenaline transporter(Human)
Esteve Pharmaceuticals

US Patent
LigandPNGBDBM562320(US11401270, Example 145 | (S)-5-(2-fluoro-4-(3- (m...)
Affinity DataKi: <100nMAssay Description:Human norepinephrine transporter (NET) enriched membranes (5 μg) were incubated with 5 nM of radiolabeled [3H]-Nisoxetin in assay buffer contain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetSodium-dependent noradrenaline transporter(Human)
Esteve Pharmaceuticals

US Patent
LigandPNGBDBM50557443(CHEMBL4748644 | US11401270, Example 54)
Affinity DataKi: <100nMAssay Description:Human norepinephrine transporter (NET) enriched membranes (5 μg) were incubated with 5 nM of radiolabeled [3H]-Nisoxetin in assay buffer contain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetSodium-dependent noradrenaline transporter(Human)
Esteve Pharmaceuticals

US Patent
LigandPNGBDBM562325(US11401270, Example 150 | (R)-(4-(1-(3- fluorophen...)
Affinity DataKi: <100nMAssay Description:Human norepinephrine transporter (NET) enriched membranes (5 μg) were incubated with 5 nM of radiolabeled [3H]-Nisoxetin in assay buffer contain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetSodium-dependent noradrenaline transporter(Human)
Esteve Pharmaceuticals

US Patent
LigandPNGBDBM562324(US11401270, Example 149 | (S)-4-(2-chloro-4-(1-(3-...)
Affinity DataKi: <100nMAssay Description:Human norepinephrine transporter (NET) enriched membranes (5 μg) were incubated with 5 nM of radiolabeled [3H]-Nisoxetin in assay buffer contain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetVoltage-dependent calcium channel subunit alpha-2/delta-1(Human)
Esteve Pharmaceuticals

US Patent
LigandPNGBDBM562324(US11401270, Example 149 | (S)-4-(2-chloro-4-(1-(3-...)
Affinity DataKi: <100nMAssay Description:Human α2δ-1 enriched membranes (2.5 μg) were incubated with 15 nM of radiolabeled [3H]-Gabapentin in assay buffer containing Hepes-KOH...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetSodium-dependent noradrenaline transporter(Human)
Esteve Pharmaceuticals

US Patent
LigandPNGBDBM562254(US11401270, Example 80 | (S)-1,8-dimethyl-4-(3-(3-...)
Affinity DataKi: <100nMAssay Description:Human norepinephrine transporter (NET) enriched membranes (5 μg) were incubated with 5 nM of radiolabeled [3H]-Nisoxetin in assay buffer contain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetVoltage-dependent calcium channel subunit alpha-2/delta-1(Human)
Esteve Pharmaceuticals

US Patent
LigandPNGBDBM562264(US11401270, Example 90)
Affinity DataKi: <100nMAssay Description:Human α2δ-1 enriched membranes (2.5 μg) were incubated with 15 nM of radiolabeled [3H]-Gabapentin in assay buffer containing Hepes-KOH...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetVoltage-dependent calcium channel subunit alpha-2/delta-1(Human)
Esteve Pharmaceuticals

US Patent
LigandPNGBDBM562264(US11401270, Example 90)
Affinity DataKi: <100nMAssay Description:Human α2δ-1 enriched membranes (2.5 μg) were incubated with 15 nM of radiolabeled [3H]-Gabapentin in assay buffer containing Hepes-KOH...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetSodium-dependent noradrenaline transporter(Human)
Esteve Pharmaceuticals

US Patent
LigandPNGBDBM562250(US11401270, Example 76 | (R)-1-isopropyl-4-(3-(3-(...)
Affinity DataKi: <100nMAssay Description:Human norepinephrine transporter (NET) enriched membranes (5 μg) were incubated with 5 nM of radiolabeled [3H]-Nisoxetin in assay buffer contain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetSodium-dependent noradrenaline transporter(Human)
Esteve Pharmaceuticals

US Patent
LigandPNGBDBM562277(US11401270, Example 103 | (S)-8-amino-1-methyl- 4-...)
Affinity DataKi: <100nMAssay Description:Human norepinephrine transporter (NET) enriched membranes (5 μg) were incubated with 5 nM of radiolabeled [3H]-Nisoxetin in assay buffer contain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetVoltage-dependent calcium channel subunit alpha-2/delta-1(Human)
Esteve Pharmaceuticals

US Patent
LigandPNGBDBM562277(US11401270, Example 103 | (S)-8-amino-1-methyl- 4-...)
Affinity DataKi: <100nMAssay Description:Human α2δ-1 enriched membranes (2.5 μg) were incubated with 15 nM of radiolabeled [3H]-Gabapentin in assay buffer containing Hepes-KOH...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetVoltage-dependent calcium channel subunit alpha-2/delta-1(Human)
Esteve Pharmaceuticals

US Patent
LigandPNGBDBM562282(US11401270, Example 108 | (S)-4-(2-fluoro-4-(3- (m...)
Affinity DataKi: <100nMAssay Description:Human α2δ-1 enriched membranes (2.5 μg) were incubated with 15 nM of radiolabeled [3H]-Gabapentin in assay buffer containing Hepes-KOH...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetVoltage-dependent calcium channel subunit alpha-2/delta-1(Human)
Esteve Pharmaceuticals

US Patent
LigandPNGBDBM562290(US11401270, Example 116 | (S)-4-(2-fluoro-4-(3- (m...)
Affinity DataKi: <100nMAssay Description:Human α2δ-1 enriched membranes (2.5 μg) were incubated with 15 nM of radiolabeled [3H]-Gabapentin in assay buffer containing Hepes-KOH...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetSodium-dependent noradrenaline transporter(Human)
Esteve Pharmaceuticals

US Patent
LigandPNGBDBM562285(US11401270, Example 111 | 8-(Ethylamino)-1- methyl...)
Affinity DataKi: <100nMAssay Description:Human norepinephrine transporter (NET) enriched membranes (5 μg) were incubated with 5 nM of radiolabeled [3H]-Nisoxetin in assay buffer contain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetVoltage-dependent calcium channel subunit alpha-2/delta-1(Human)
Esteve Pharmaceuticals

US Patent
LigandPNGBDBM562295(US11401270, Example 120 | (S)-4-(3-fluoro-5-(3- (m...)
Affinity DataKi: <100nMAssay Description:Human α2δ-1 enriched membranes (2.5 μg) were incubated with 15 nM of radiolabeled [3H]-Gabapentin in assay buffer containing Hepes-KOH...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetVoltage-dependent calcium channel subunit alpha-2/delta-1(Human)
Esteve Pharmaceuticals

US Patent
LigandPNGBDBM562296(US11401270, Example 121 | 4-(3-Fluoro-5-(1-(3- flu...)
Affinity DataKi: <100nMAssay Description:Human α2δ-1 enriched membranes (2.5 μg) were incubated with 15 nM of radiolabeled [3H]-Gabapentin in assay buffer containing Hepes-KOH...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetSodium-dependent noradrenaline transporter(Human)
Esteve Pharmaceuticals

US Patent
LigandPNGBDBM562284(US11401270, Example 110 | 1,8-Dimethyl-4-(4-(3- (m...)
Affinity DataKi: <100nMAssay Description:Human norepinephrine transporter (NET) enriched membranes (5 μg) were incubated with 5 nM of radiolabeled [3H]-Nisoxetin in assay buffer contain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetSodium-dependent noradrenaline transporter(Human)
Esteve Pharmaceuticals

US Patent
LigandPNGBDBM562289(US11401270, Example 115 | 4-(4-(1-(4- Fluorophenyl...)
Affinity DataKi: <100nMAssay Description:Human norepinephrine transporter (NET) enriched membranes (5 μg) were incubated with 5 nM of radiolabeled [3H]-Nisoxetin in assay buffer contain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetVoltage-dependent calcium channel subunit alpha-2/delta-1(Human)
Esteve Pharmaceuticals

US Patent
LigandPNGBDBM562299(US11401270, Example 124 | (S)-2-methyl-5-(2- methy...)
Affinity DataKi: <100nMAssay Description:Human α2δ-1 enriched membranes (2.5 μg) were incubated with 15 nM of radiolabeled [3H]-Gabapentin in assay buffer containing Hepes-KOH...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetVoltage-dependent calcium channel subunit alpha-2/delta-1(Human)
Esteve Pharmaceuticals

US Patent
LigandPNGBDBM562300(US11401270, Example 125 | (S)-7-fluoro-1-methyl-4-...)
Affinity DataKi: <100nMAssay Description:Human α2δ-1 enriched membranes (2.5 μg) were incubated with 15 nM of radiolabeled [3H]-Gabapentin in assay buffer containing Hepes-KOH...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetVoltage-dependent calcium channel subunit alpha-2/delta-1(Human)
Esteve Pharmaceuticals

US Patent
LigandPNGBDBM562298(US11401270, Example 123 | 4-(2-Fluoro-4-(1-(3- flu...)
Affinity DataKi: <100nMAssay Description:Human α2δ-1 enriched membranes (2.5 μg) were incubated with 15 nM of radiolabeled [3H]-Gabapentin in assay buffer containing Hepes-KOH...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetSodium-dependent noradrenaline transporter(Human)
Esteve Pharmaceuticals

US Patent
LigandPNGBDBM562266(US11401270, Example 92 | (S)-8-(ethylamino)-1- met...)
Affinity DataKi: <100nMAssay Description:Human norepinephrine transporter (NET) enriched membranes (5 μg) were incubated with 5 nM of radiolabeled [3H]-Nisoxetin in assay buffer contain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetVoltage-dependent calcium channel subunit alpha-2/delta-1(Human)
Esteve Pharmaceuticals

US Patent
LigandPNGBDBM562273(US11401270, Example 99 | 1-Methyl-4-(4-(3- (methyl...)
Affinity DataKi: <100nMAssay Description:Human α2δ-1 enriched membranes (2.5 μg) were incubated with 15 nM of radiolabeled [3H]-Gabapentin in assay buffer containing Hepes-KOH...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetVoltage-dependent calcium channel subunit alpha-2/delta-1(Human)
Esteve Pharmaceuticals

US Patent
LigandPNGBDBM562277(US11401270, Example 103 | (S)-8-amino-1-methyl- 4-...)
Affinity DataKi: <100nMAssay Description:Human α2δ-1 enriched membranes (2.5 μg) were incubated with 15 nM of radiolabeled [3H]-Gabapentin in assay buffer containing Hepes-KOH...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetSodium-dependent noradrenaline transporter(Human)
Esteve Pharmaceuticals

US Patent
LigandPNGBDBM562273(US11401270, Example 99 | 1-Methyl-4-(4-(3- (methyl...)
Affinity DataKi: <100nMAssay Description:Human norepinephrine transporter (NET) enriched membranes (5 μg) were incubated with 5 nM of radiolabeled [3H]-Nisoxetin in assay buffer contain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetVoltage-dependent calcium channel subunit alpha-2/delta-1(Human)
Esteve Pharmaceuticals

US Patent
LigandPNGBDBM562281(US11401270, Example 107 | (S)-1-methyl-4-(2- methy...)
Affinity DataKi: <100nMAssay Description:Human α2δ-1 enriched membranes (2.5 μg) were incubated with 15 nM of radiolabeled [3H]-Gabapentin in assay buffer containing Hepes-KOH...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetVoltage-dependent calcium channel subunit alpha-2/delta-1(Human)
Esteve Pharmaceuticals

US Patent
LigandPNGBDBM562273(US11401270, Example 99 | 1-Methyl-4-(4-(3- (methyl...)
Affinity DataKi: <100nMAssay Description:Human α2δ-1 enriched membranes (2.5 μg) were incubated with 15 nM of radiolabeled [3H]-Gabapentin in assay buffer containing Hepes-KOH...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetVoltage-dependent calcium channel subunit alpha-2/delta-1(Human)
Esteve Pharmaceuticals

US Patent
LigandPNGBDBM562282(US11401270, Example 108 | (S)-4-(2-fluoro-4-(3- (m...)
Affinity DataKi: <100nMAssay Description:Human α2δ-1 enriched membranes (2.5 μg) were incubated with 15 nM of radiolabeled [3H]-Gabapentin in assay buffer containing Hepes-KOH...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetSodium-dependent noradrenaline transporter(Human)
Esteve Pharmaceuticals

US Patent
LigandPNGBDBM562307(US11401270, Example 132 | (S)-4-(2-fluoro-4-(3- (m...)
Affinity DataKi: <100nMAssay Description:Human norepinephrine transporter (NET) enriched membranes (5 μg) were incubated with 5 nM of radiolabeled [3H]-Nisoxetin in assay buffer contain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetSodium-dependent noradrenaline transporter(Human)
Esteve Pharmaceuticals

US Patent
LigandPNGBDBM562306(US11401270, Example 131 | 8-Amino-4-(2-fluoro-4- (...)
Affinity DataKi: <100nMAssay Description:Human norepinephrine transporter (NET) enriched membranes (5 μg) were incubated with 5 nM of radiolabeled [3H]-Nisoxetin in assay buffer contain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetVoltage-dependent calcium channel subunit alpha-2/delta-1(Human)
Esteve Pharmaceuticals

US Patent
LigandPNGBDBM562306(US11401270, Example 131 | 8-Amino-4-(2-fluoro-4- (...)
Affinity DataKi: <100nMAssay Description:Human α2δ-1 enriched membranes (2.5 μg) were incubated with 15 nM of radiolabeled [3H]-Gabapentin in assay buffer containing Hepes-KOH...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetSodium-dependent noradrenaline transporter(Human)
Esteve Pharmaceuticals

US Patent
LigandPNGBDBM562311(US11401270, Example 136 | (S)-4-(2-fluoro-4-(1-(3-...)
Affinity DataKi: <100nMAssay Description:Human norepinephrine transporter (NET) enriched membranes (5 μg) were incubated with 5 nM of radiolabeled [3H]-Nisoxetin in assay buffer contain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetVoltage-dependent calcium channel subunit alpha-2/delta-1(Human)
Esteve Pharmaceuticals

US Patent
LigandPNGBDBM562311(US11401270, Example 136 | (S)-4-(2-fluoro-4-(1-(3-...)
Affinity DataKi: <100nMAssay Description:Human α2δ-1 enriched membranes (2.5 μg) were incubated with 15 nM of radiolabeled [3H]-Gabapentin in assay buffer containing Hepes-KOH...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetVoltage-dependent calcium channel subunit alpha-2/delta-1(Human)
Esteve Pharmaceuticals

US Patent
LigandPNGBDBM562324(US11401270, Example 149 | (S)-4-(2-chloro-4-(1-(3-...)
Affinity DataKi: <100nMAssay Description:Human α2δ-1 enriched membranes (2.5 μg) were incubated with 15 nM of radiolabeled [3H]-Gabapentin in assay buffer containing Hepes-KOH...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetSodium-dependent noradrenaline transporter(Human)
Esteve Pharmaceuticals

US Patent
LigandPNGBDBM562309(US11401270, Example 134 | (S)-2-methoxy-5-(2- meth...)
Affinity DataKi: <100nMAssay Description:Human norepinephrine transporter (NET) enriched membranes (5 μg) were incubated with 5 nM of radiolabeled [3H]-Nisoxetin in assay buffer contain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetVoltage-dependent calcium channel subunit alpha-2/delta-1(Human)
Esteve Pharmaceuticals

US Patent
LigandPNGBDBM562309(US11401270, Example 134 | (S)-2-methoxy-5-(2- meth...)
Affinity DataKi: <100nMAssay Description:Human α2δ-1 enriched membranes (2.5 μg) were incubated with 15 nM of radiolabeled [3H]-Gabapentin in assay buffer containing Hepes-KOH...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetSodium-dependent noradrenaline transporter(Human)
Esteve Pharmaceuticals

US Patent
LigandPNGBDBM562313(US11401270, Example 138 | (S)-8-amino-4-(2-chloro-...)
Affinity DataKi: <100nMAssay Description:Human norepinephrine transporter (NET) enriched membranes (5 μg) were incubated with 5 nM of radiolabeled [3H]-Nisoxetin in assay buffer contain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetVoltage-dependent calcium channel subunit alpha-2/delta-1(Human)
Esteve Pharmaceuticals

US Patent
LigandPNGBDBM562327(US11401270, Example 152 | (S)-4-(2-fluoro-4-(1-(2-...)
Affinity DataKi: <100nMAssay Description:Human α2δ-1 enriched membranes (2.5 μg) were incubated with 15 nM of radiolabeled [3H]-Gabapentin in assay buffer containing Hepes-KOH...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

TargetVoltage-dependent calcium channel subunit alpha-2/delta-1(Human)
Esteve Pharmaceuticals

US Patent
LigandPNGBDBM562313(US11401270, Example 138 | (S)-8-amino-4-(2-chloro-...)
Affinity DataKi: <100nMAssay Description:Human α2δ-1 enriched membranes (2.5 μg) were incubated with 15 nM of radiolabeled [3H]-Gabapentin in assay buffer containing Hepes-KOH...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

Displayed 1 to 50 (of 308 total ) | Next | Last >>
Jump to: